Incyte: Phase 2 Trial Results Of Niktimvo In Chronic Graft-Versus-Host Disease Meet Primary Goal
19/9 03:00
(RTTNews) - Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that results from the pivotal Phase 2 AGAVE-201 trial of Niktimvo(axatilimab-csfr), an anti-CSF-1R antibody, in adult and pediatric patients with recurrent/refractory active chronic graft-versus-host disease or...